PHC (6523) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
15 May, 2026Executive summary
FY 2025 revenue reached JPY 364.4 billion, up 0.8% year-on-year, with record highs in both revenue and operating profit, driven by strong BGM performance in Europe and the U.S. despite market contraction.
Operating profit exceeded forecasts, rising 0.5% to JPY 22.7 billion, supported by high-margin BGM, cost reductions, and the CGM business transfer.
Profit attributable to owners of parent fell 95.3% to JPY 500 million, mainly due to unrealized FX loss of JPY 10.5 billion and higher tax expenses.
Dividend maintained at JPY 42 per share for the full year.
Strategic restructuring, portfolio management, and sustainability initiatives, including CGM divestment, are expected to drive significant profit growth in FY 2026.
Financial highlights
FY 2025 revenue was JPY 364.4 billion (+0.8% YoY); operating profit JPY 22.7 billion (+0.5% YoY); profit attributable to owners JPY 0.5 billion (-95.3% YoY).
Adjusted EBITDA increased 3.8% to JPY 52.0 billion; ROIC stood at 3.9%.
Dividend per share was JPY 42 (unchanged YoY), with a payout ratio of 1,077.3%.
Net debt leverage ratio improved to 3.7x; gross debt reduced by JPY 20.7 billion; refinancing enhanced financial flexibility.
Operating cash flow was JPY 42.5 billion, maintaining stability for three consecutive years.
Outlook and guidance
FY 2026 revenue forecast is JPY 359.7 billion, down 1.3% YoY due to FX and CGM transfer, but up 1.2% excluding FX.
Operating profit target is JPY 27 billion (+19.0% YoY), with a margin improvement to 7.5%.
Profit attributable to owners of parent projected at JPY 15.4 billion, EPS at JPY 122.
Dividend expected to remain at JPY 42 per share.
Segment reorganization and business unit renaming will take effect in FY2027.
Latest events from PHC
- FX losses drove a sharp profit drop despite stable revenue and strong BGM growth.6523
Q3 202612 Feb 2026 - Profit and revenue up 4.0% year-over-year, driven by CGM, e-prescriptions, and Pathology.6523
Q3 20253 Feb 2026 - Operating profit up 12.7% YoY despite flat revenue and FX-driven net loss.6523
Q2 20263 Feb 2026 - Q1 revenue and profit grew, but FX losses caused a net loss; full-year guidance unchanged.6523
Q1 20252 Feb 2026 - Operating profit more than doubled year-on-year, with guidance and dividend unchanged.6523
Q2 202512 Jan 2026 - FY2024 profit rebounded on cost cuts; FY2025 profit to fall on restructuring and tariffs.6523
Q4 202526 Nov 2025 - Operating profit surged 89.6% year-on-year despite a 1.6% revenue decline.6523
Q1 202623 Nov 2025